Advanced Cell Tech Stock Total Debt

T2N Stock   0.21  0.01  4.55%   
ADVANCED CELL TECH fundamentals help investors to digest information that contributes to ADVANCED CELL's financial success or failures. It also enables traders to predict the movement of ADVANCED Stock. The fundamental analysis module provides a way to measure ADVANCED CELL's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ADVANCED CELL stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

ADVANCED CELL TECH Company Total Debt Analysis

ADVANCED CELL's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Total Debt

 = 

Bonds

+

Notes

More About Total Debt | All Equity Analysis
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Based on the latest financial disclosure, ADVANCED CELL TECH has a Total Debt of 0.0. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Total Debt (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).

ADVANCED Total Debt Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ADVANCED CELL's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ADVANCED CELL could also be used in its relative valuation, which is a method of valuing ADVANCED CELL by comparing valuation metrics of similar companies.
ADVANCED CELL is currently under evaluation in total debt category among its peers.

About ADVANCED CELL Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze ADVANCED CELL TECH's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADVANCED CELL using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADVANCED CELL TECH based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in ADVANCED Stock

ADVANCED CELL financial ratios help investors to determine whether ADVANCED Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ADVANCED with respect to the benefits of owning ADVANCED CELL security.